Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 12/20 | 0.51 |
| ▸ | CLK2 | P49760 | 9/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.50 |
| ▸ | CLK3 | P49761 | 8/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17638769 | 0.94 | WNT1 (0.51) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17564026 | 0.90 | WNT1 (0.51) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17638796 | 0.90 | WNT1 (0.50) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17638308 | 0.89 | WNT1 (0.61) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17638736 | 0.89 | WNT1 (0.58) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17638717 | 0.89 | WNT1 (0.51) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17638509 | 0.88 | CLK2 (0.53) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17587526 | 0.88 | CLK2 (0.58) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17638479 | 0.88 | WNT1 (0.63) | WNT1CLK2DYRK1ACLK3TGFBR1 | |
| SCHEMBL17638427 | 0.88 | WNT1 (0.54) | WNT1CLK2DYRK1ACLK3TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280166-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20190055238-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-02-21 | — | — | US | disclosed |
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180148444-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-05-31 | — | — | US | disclosed |
| US-20180148444-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-05-31 | — | — | US | disclosed |
| US-9738638-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738638-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160090380-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-31 | — | — | US | disclosed |
| US-20160090380-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148444-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885CLK2 907/4885DYRK1A 707/4885 |
| US-10280166-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | WNT1 1/4885CLK2 907/4885DYRK1A 707/4885 |
| US-20190055238-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885CLK2 907/4885DYRK1A 707/4885 |
| US-20160090380-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885CLK2 907/4885DYRK1A 707/4885 |
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | WNT1 1/4885CLK2 907/4885DYRK1A 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.